{"transactions":[{"id":718515,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":33006,"kind":"person","name":"Zaki Mohamed","position":1,"cik":"0002000697","reported_name":"Zaki Mohamed","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2026-07-02T21:17:13.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":213900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units (\"RSUs\") granted on June 30, 2026 pursuant to an incentive award letter agreement. The RSUs will vest upon the earlier of (i) June 30, 2027 or (ii) termination of employment by the Issuer without cause or by the reporting person for good reason, subject to the reporting person's continued employment with the Issuer on the vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":896317,"source":{"system":"sec-edgar","filing":"0001628280-26-047036","document":"wk-form4_1783027029.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000697/000162828026047036/wk-form4_1783027029.xml","form_type":"4"}},{"id":717587,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2026-07-02T21:16:41.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":221100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units (\"RSUs\") granted on June 30, 2026 pursuant to an incentive award letter agreement. The RSUs will vest upon the earlier of (i) June 30, 2027 or (ii) termination of employment by the Issuer without cause or by the reporting person for good reason, subject to the reporting person's continued employment with the Issuer on the vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":841640,"source":{"system":"sec-edgar","filing":"0001628280-26-047034","document":"wk-form4_1783026998.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235635/000162828026047034/wk-form4_1783026998.xml","form_type":"4"}},{"id":718025,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":32873,"kind":"person","name":"Carmona Jose","position":1,"cik":"0001693612","reported_name":"Carmona Jose","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2026-07-02T21:16:03.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":203700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units (\"RSUs\") granted on June 30, 2026 pursuant to an incentive award letter agreement. The RSUs will vest upon the earlier of (i) June 30, 2027 or (ii) termination of employment by the Issuer without cause or by the reporting person for good reason, subject to the reporting person's continued employment with the Issuer on the vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":938076,"source":{"system":"sec-edgar","filing":"0001628280-26-047033","document":"wk-form4_1783026959.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693612/000162828026047033/wk-form4_1783026959.xml","form_type":"4"}},{"id":718301,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":32949,"kind":"person","name":"MALLIK AMEET","position":1,"cik":"0001861441","reported_name":"MALLIK AMEET","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2026-07-02T21:15:30.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":675000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units (\"RSUs\") granted on June 30, 2026 pursuant to an incentive award letter agreement. The RSUs will vest upon the earlier of (i) June 30, 2027 or (ii) termination of employment by the Issuer without cause or by the reporting person for good reason, subject to the reporting person's continued employment with the Issuer on the vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":2121769,"source":{"system":"sec-edgar","filing":"0001628280-26-047031","document":"wk-form4_1783026927.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861441/000162828026047031/wk-form4_1783026927.xml","form_type":"4"}},{"id":750797,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-03T21:03:43.000Z","date":"2026-06-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":12600,"price":3.08,"value":38808.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":112805,"source":{"system":"sec-edgar","filing":"0001628280-26-040493","document":"wk-form4_1780520620.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1656998/000162828026040493/wk-form4_1780520620.xml","form_type":"4"}},{"id":750796,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-03T21:03:43.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the annual grant of restricted stock units (\"RSUs\") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer.  Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":125405,"source":{"system":"sec-edgar","filing":"0001628280-26-040493","document":"wk-form4_1780520620.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656998/000162828026040493/wk-form4_1780520620.xml","form_type":"4"}},{"id":751583,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":30346,"kind":"person","name":"Squarer Ron","position":1,"cik":"0001454001","reported_name":"Squarer Ron","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-03T21:03:29.000Z","date":"2026-06-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":15196,"price":3.08,"value":46803.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":123431,"source":{"system":"sec-edgar","filing":"0001628280-26-040492","document":"wk-form4_1780520606.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1454001/000162828026040492/wk-form4_1780520606.xml","form_type":"4"}},{"id":751582,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":30346,"kind":"person","name":"Squarer Ron","position":1,"cik":"0001454001","reported_name":"Squarer Ron","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-03T21:03:29.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the annual grant of restricted stock units (\"RSUs\") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer.  Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":138627,"source":{"system":"sec-edgar","filing":"0001628280-26-040492","document":"wk-form4_1780520606.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454001/000162828026040492/wk-form4_1780520606.xml","form_type":"4"}},{"id":750849,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":31980,"kind":"person","name":"Sandor Victor","position":1,"cik":"0001620368","reported_name":"Sandor Victor","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-03T21:03:16.000Z","date":"2026-06-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":12600,"price":3.08,"value":38808.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":140686,"source":{"system":"sec-edgar","filing":"0001628280-26-040491","document":"wk-form4_1780520592.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1620368/000162828026040491/wk-form4_1780520592.xml","form_type":"4"}},{"id":750848,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":31980,"kind":"person","name":"Sandor Victor","position":1,"cik":"0001620368","reported_name":"Sandor Victor","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-03T21:03:16.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the annual grant of restricted stock units (\"RSUs\") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer.  Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":153286,"source":{"system":"sec-edgar","filing":"0001628280-26-040491","document":"wk-form4_1780520592.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1620368/000162828026040491/wk-form4_1780520592.xml","form_type":"4"}},{"id":750715,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":41602,"kind":"person","name":"Monges Viviane","position":1,"cik":"0001838204","reported_name":"Monges Viviane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-03T21:03:03.000Z","date":"2026-06-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":2596,"price":3.08,"value":7995.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":186447,"source":{"system":"sec-edgar","filing":"0001628280-26-040490","document":"wk-form4_1780520578.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1771910/000162828026040490/wk-form4_1780520578.xml","form_type":"4"}},{"id":750714,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":41602,"kind":"person","name":"Monges Viviane","position":1,"cik":"0001838204","reported_name":"Monges Viviane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-03T21:03:03.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the annual grant of restricted stock units (\"RSUs\") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer.  Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":189043,"source":{"system":"sec-edgar","filing":"0001628280-26-040490","document":"wk-form4_1780520578.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1771910/000162828026040490/wk-form4_1780520578.xml","form_type":"4"}},{"id":750830,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":37129,"kind":"person","name":"BIZZARI JEAN-PIERRE","position":1,"cik":"0001630914","reported_name":"BIZZARI JEAN-PIERRE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-03T21:02:24.000Z","date":"2026-06-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":12600,"price":3.08,"value":38808.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":139302,"source":{"system":"sec-edgar","filing":"0001628280-26-040488","document":"wk-form4_1780520540.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1630914/000162828026040488/wk-form4_1780520540.xml","form_type":"4"}},{"id":750829,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":37129,"kind":"person","name":"BIZZARI JEAN-PIERRE","position":1,"cik":"0001630914","reported_name":"BIZZARI JEAN-PIERRE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-03T21:02:24.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the annual grant of restricted stock units (\"RSUs\") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer.  Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":151902,"source":{"system":"sec-edgar","filing":"0001628280-26-040488","document":"wk-form4_1780520540.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1630914/000162828026040488/wk-form4_1780520540.xml","form_type":"4"}},{"id":751143,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":37659,"kind":"person","name":"Coughlin Timothy","position":1,"cik":"0001376043","reported_name":"Coughlin Timothy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-03T21:02:03.000Z","date":"2026-06-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":12600,"price":3.08,"value":38808.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":72400,"source":{"system":"sec-edgar","filing":"0001628280-26-040487","document":"wk-form4_1780520520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1376043/000162828026040487/wk-form4_1780520520.xml","form_type":"4"}},{"id":751142,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":37659,"kind":"person","name":"Coughlin Timothy","position":1,"cik":"0001376043","reported_name":"Coughlin Timothy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-03T21:02:03.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the annual grant of restricted stock units (\"RSUs\") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer.  Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":85000,"source":{"system":"sec-edgar","filing":"0001628280-26-040487","document":"wk-form4_1780520520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1376043/000162828026040487/wk-form4_1780520520.xml","form_type":"4"}},{"id":752222,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":41821,"kind":"person","name":"Hug Peter","position":1,"cik":"0002000702","reported_name":"Hug Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-03T17:02:36.000Z","date":"2026-06-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":2156,"price":3.08,"value":6640.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":263344,"source":{"system":"sec-edgar","filing":"0001628280-26-040489","document":"wk-form4_1780520554.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2000702/000162828026040489/wk-form4_1780520554.xml","form_type":"4"}},{"id":752221,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":41821,"kind":"person","name":"Hug Peter","position":1,"cik":"0002000702","reported_name":"Hug Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-03T17:02:36.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the annual grant of restricted stock units (\"RSUs\") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer.  Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":265500,"source":{"system":"sec-edgar","filing":"0001628280-26-040489","document":"wk-form4_1780520554.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000702/000162828026040489/wk-form4_1780520554.xml","form_type":"4"}},{"id":819353,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-03T01:00:23.000Z","date":"2026-04-02","kind":"sale","planned":false,"acquired":false,"shares":2529491,"price":3.279,"value":8294200.989,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.25 to $3.77, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are directly owned by RedCo II Master Fund, L.P."}],"balance_after":10265297,"source":{"system":"sec-edgar","filing":"0001104659-26-039359","document":"tm2611043-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465926039359/tm2611043-1_4seq1.xml","form_type":"4"}},{"id":819352,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-03T01:00:23.000Z","date":"2026-04-02","kind":"sale","planned":false,"acquired":false,"shares":2634506,"price":3.279,"value":8638545.174,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.25 to $3.77, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC (\"Redmile\"), including RedCo II Master Fund, L.P., and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":12666731,"source":{"system":"sec-edgar","filing":"0001104659-26-039359","document":"tm2611043-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465926039359/tm2611043-1_4seq1.xml","form_type":"4"}},{"id":819351,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-03T01:00:23.000Z","date":"2026-04-01","kind":"sale","planned":false,"acquired":false,"shares":162517,"price":3.799,"value":617402.083,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.70 to $3.83, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are directly owned by RedCo II Master Fund, L.P."}],"balance_after":12794788,"source":{"system":"sec-edgar","filing":"0001104659-26-039359","document":"tm2611043-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465926039359/tm2611043-1_4seq1.xml","form_type":"4"}},{"id":819350,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-03T01:00:23.000Z","date":"2026-04-01","kind":"sale","planned":false,"acquired":false,"shares":169265,"price":3.799,"value":643037.735,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.70 to $3.83, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC (\"Redmile\"), including RedCo II Master Fund, L.P., and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":15301237,"source":{"system":"sec-edgar","filing":"0001104659-26-039359","document":"tm2611043-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465926039359/tm2611043-1_4seq1.xml","form_type":"4"}},{"id":819349,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-03T01:00:23.000Z","date":"2026-03-31","kind":"sale","planned":false,"acquired":false,"shares":188407,"price":3.752,"value":706903.064,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.63 to $3.81, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are directly owned by RedCo II Master Fund, L.P."}],"balance_after":12957305,"source":{"system":"sec-edgar","filing":"0001104659-26-039359","document":"tm2611043-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465926039359/tm2611043-1_4seq1.xml","form_type":"4"}},{"id":819348,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-03T01:00:23.000Z","date":"2026-03-31","kind":"sale","planned":false,"acquired":false,"shares":196229,"price":3.752,"value":736251.208,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.63 to $3.81, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC (\"Redmile\"), including RedCo II Master Fund, L.P., and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":15470502,"source":{"system":"sec-edgar","filing":"0001104659-26-039359","document":"tm2611043-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465926039359/tm2611043-1_4seq1.xml","form_type":"4"}},{"id":897383,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":33006,"kind":"person","name":"Zaki Mohamed","position":1,"cik":"0002000697","reported_name":"Zaki Mohamed","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2026-02-18T22:43:44.000Z","date":"2026-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":24603,"price":3.99,"value":98165.97,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":682417,"source":{"system":"sec-edgar","filing":"0001628280-26-009282","document":"wk-form4_1771454620.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2000697/000162828026009282/wk-form4_1771454620.xml","form_type":"4"}},{"id":897382,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":33006,"kind":"person","name":"Zaki Mohamed","position":1,"cik":"0002000697","reported_name":"Zaki Mohamed","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2026-02-18T22:43:44.000Z","date":"2026-02-13","kind":"grant","planned":false,"acquired":true,"shares":285200,"price":3.99,"value":1137948.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Common Shares to be delivered in settlement of a restricted share unit award which vests one-third on the first anniversary of the grant date, which grant date is February 13, 2026, and then one-third on each anniversary date thereafter, upon continued service through the designated vesting event."}],"balance_after":707020,"source":{"system":"sec-edgar","filing":"0001628280-26-009282","document":"wk-form4_1771454620.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000697/000162828026009282/wk-form4_1771454620.xml","form_type":"4"}},{"id":896212,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2026-02-18T22:43:12.000Z","date":"2026-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":33294,"price":3.99,"value":132843.06,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":620540,"source":{"system":"sec-edgar","filing":"0001628280-26-009280","document":"wk-form4_1771454589.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235635/000162828026009280/wk-form4_1771454589.xml","form_type":"4"}},{"id":896211,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2026-02-18T22:43:12.000Z","date":"2026-02-13","kind":"grant","planned":false,"acquired":true,"shares":294800,"price":3.99,"value":1176252.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Common Shares to be delivered in settlement of a restricted share unit award which vests one-third on the first anniversary of the grant date, which grant date is February 13, 2026, and then one-third on each anniversary date thereafter, upon continued service through the designated vesting event."}],"balance_after":653834,"source":{"system":"sec-edgar","filing":"0001628280-26-009280","document":"wk-form4_1771454589.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235635/000162828026009280/wk-form4_1771454589.xml","form_type":"4"}},{"id":896902,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":32873,"kind":"person","name":"Carmona Jose","position":1,"cik":"0001693612","reported_name":"Carmona Jose","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2026-02-18T22:42:53.000Z","date":"2026-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":25880,"price":3.99,"value":103261.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":734376,"source":{"system":"sec-edgar","filing":"0001628280-26-009278","document":"wk-form4_1771454570.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1693612/000162828026009278/wk-form4_1771454570.xml","form_type":"4"}},{"id":896901,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":32873,"kind":"person","name":"Carmona Jose","position":1,"cik":"0001693612","reported_name":"Carmona Jose","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2026-02-18T22:42:53.000Z","date":"2026-02-13","kind":"grant","planned":false,"acquired":true,"shares":271600,"price":3.99,"value":1083684.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Common Shares to be delivered in settlement of a restricted share unit award which vests one-third on the first anniversary of the grant date, which grant date is February 13, 2026, and then one-third on each anniversary date thereafter, upon continued service through the designated vesting event."}],"balance_after":760256,"source":{"system":"sec-edgar","filing":"0001628280-26-009278","document":"wk-form4_1771454570.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693612/000162828026009278/wk-form4_1771454570.xml","form_type":"4"}},{"id":897159,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":32949,"kind":"person","name":"MALLIK AMEET","position":1,"cik":"0001861441","reported_name":"MALLIK AMEET","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2026-02-18T22:39:54.000Z","date":"2026-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":103231,"price":3.99,"value":411891.69,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":1446769,"source":{"system":"sec-edgar","filing":"0001628280-26-009275","document":"wk-form4_1771454386.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861441/000162828026009275/wk-form4_1771454386.xml","form_type":"4"}},{"id":897158,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":32949,"kind":"person","name":"MALLIK AMEET","position":1,"cik":"0001861441","reported_name":"MALLIK AMEET","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2026-02-18T22:39:54.000Z","date":"2026-02-13","kind":"grant","planned":false,"acquired":true,"shares":900000,"price":3.99,"value":3591000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Common Shares to be delivered in settlement of a restricted share unit award which vests one-third on the first anniversary of the grant date, which grant date is February 13, 2026, and then one-third on each anniversary date thereafter, upon continued service through the designated vesting event."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Balance reflects the prior transfer of 669,101 Common Shares from the Reporting Person to a grantor retained annuity trust, which transfer is exempt from Section 16(b) pursuant to Rule 16a-13. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":1550000,"source":{"system":"sec-edgar","filing":"0001628280-26-009275","document":"wk-form4_1771454386.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861441/000162828026009275/wk-form4_1771454386.xml","form_type":"4"}},{"id":897377,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":65933,"kind":"person","name":"Kallebo Lisa Michelle","position":1,"cik":"0002000724","reported_name":"Kallebo Lisa Michelle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2026-02-18T17:44:04.000Z","date":"2026-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":5433,"price":3.99,"value":21677.67,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":128224,"source":{"system":"sec-edgar","filing":"0001628280-26-009283","document":"wk-form4_1771454641.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2000724/000162828026009283/wk-form4_1771454641.xml","form_type":"4"}},{"id":897376,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":65933,"kind":"person","name":"Kallebo Lisa Michelle","position":1,"cik":"0002000724","reported_name":"Kallebo Lisa Michelle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2026-02-18T17:44:04.000Z","date":"2026-02-13","kind":"grant","planned":false,"acquired":true,"shares":62900,"price":3.99,"value":250971.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Common Shares to be delivered in settlement of a restricted share unit award which vests one-third on the first anniversary of the grant date, which grant date is February 13, 2026, and then one-third on each anniversary date thereafter, upon continued service through the designated vesting event."}],"balance_after":133657,"source":{"system":"sec-edgar","filing":"0001628280-26-009283","document":"wk-form4_1771454641.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000724/000162828026009283/wk-form4_1771454641.xml","form_type":"4"}},{"id":976308,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":32949,"kind":"person","name":"MALLIK AMEET","position":1,"cik":"0001861441","reported_name":"MALLIK AMEET","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2025-12-09T22:10:09.000Z","date":"2025-12-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":233146,"price":3.29,"value":767050.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":1319101,"source":{"system":"sec-edgar","filing":"0001628280-25-056172","document":"wk-form4_1765318205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861441/000162828025056172/wk-form4_1765318205.xml","form_type":"4"}},{"id":976383,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":33006,"kind":"person","name":"Zaki Mohamed","position":1,"cik":"0002000697","reported_name":"Zaki Mohamed","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2025-12-09T22:09:56.000Z","date":"2025-12-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":41068,"price":3.29,"value":135113.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":421820,"source":{"system":"sec-edgar","filing":"0001628280-25-056171","document":"wk-form4_1765318192.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000697/000162828025056171/wk-form4_1765318192.xml","form_type":"4"}},{"id":975787,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2025-12-09T22:09:31.000Z","date":"2025-12-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":49508,"price":3.29,"value":162881.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":359034,"source":{"system":"sec-edgar","filing":"0001628280-25-056169","document":"wk-form4_1765318168.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235635/000162828025056169/wk-form4_1765318168.xml","form_type":"4"}},{"id":976092,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":32873,"kind":"person","name":"Carmona Jose","position":1,"cik":"0001693612","reported_name":"Carmona Jose","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2025-12-09T22:09:09.000Z","date":"2025-12-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":53236,"price":3.29,"value":175146.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":488656,"source":{"system":"sec-edgar","filing":"0001628280-25-056168","document":"wk-form4_1765318145.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693612/000162828025056168/wk-form4_1765318145.xml","form_type":"4"}},{"id":976381,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":65933,"kind":"person","name":"Kallebo Lisa Michelle","position":1,"cik":"0002000724","reported_name":"Kallebo Lisa Michelle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2025-12-09T17:09:44.000Z","date":"2025-12-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":7140,"price":3.29,"value":23490.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":70757,"source":{"system":"sec-edgar","filing":"0001628280-25-056170","document":"wk-form4_1765318181.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000724/000162828025056170/wk-form4_1765318181.xml","form_type":"4"}},{"id":1012543,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2025-10-29T01:00:10.000Z","date":"2025-10-27","kind":"purchase","planned":false,"acquired":true,"shares":3846153,"price":3.9,"value":14999996.7,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price of the Pre-Funded Warrants is CHF 0.08 per Pre-Funded Warrant Share. Based on the October 12, 2025 exchange rate of approximately $1.25 to CHF 1.00, the exercise price of the Pre-Funded Warrants in US Dollars as of October 12, 2025 was approximately $0.10."},{"field":"kind","element":"transactionCoding","label":"F1","text":"RedCo II Master Fund, L.P. (\"RedCo II\") acquired the reported pre-funded warrants to purchase Common Shares (the \"Pre-Funded Warrants\") in a private placement by the Issuer pursuant to the terms of a securities purchase agreement, dated October 12, 2025 (the \"Purchase Agreement\"), by and among the Issuer and RedCo II. The purchase price per Pre-Funded Warrants is $3.90, which is the price per Common Share in the private placement minus the exercise price per Pre-Funded Warrant. The closing of the private placement occurred on October 27, 2025 following the satisfaction of the closing conditions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrants are exercisable by the holder at any time on or after the closing date of the private placement until the tenth anniversary of such closing date, subject to a 9.99% beneficial ownership blocker. At any time during the last 90 days of the term of the Pre-Funded Warrants, the holder thereof may exchange a Pre-Funded Warrant with the Issuer for a new Pre-Funded Warrant to purchase the number of Pre-Funded Warrant Shares then remaining under such Pre-Funded Warrant, with a subsequent ten-year exercise period."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"These reported securities are directly owned by RedCo II and this transaction is a repetition of the same transaction disclosed in the row above to disclose this fund's direct ownership."}],"balance_after":3846153,"derivative":{"exercise_date":"2025-10-27","underlying":"Common Share","underlying_shares":3846153},"source":{"system":"sec-edgar","filing":"0001104659-25-103336","document":"tm2529454-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465925103336/tm2529454-1_4seq1.xml","form_type":"4"}},{"id":1012542,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2025-10-29T01:00:10.000Z","date":"2025-10-27","kind":"purchase","planned":false,"acquired":true,"shares":3846153,"price":3.9,"value":14999996.7,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price of the Pre-Funded Warrants is CHF 0.08 per Pre-Funded Warrant Share. Based on the October 12, 2025 exchange rate of approximately $1.25 to CHF 1.00, the exercise price of the Pre-Funded Warrants in US Dollars as of October 12, 2025 was approximately $0.10."},{"field":"kind","element":"transactionCoding","label":"F1","text":"RedCo II Master Fund, L.P. (\"RedCo II\") acquired the reported pre-funded warrants to purchase Common Shares (the \"Pre-Funded Warrants\") in a private placement by the Issuer pursuant to the terms of a securities purchase agreement, dated October 12, 2025 (the \"Purchase Agreement\"), by and among the Issuer and RedCo II. The purchase price per Pre-Funded Warrants is $3.90, which is the price per Common Share in the private placement minus the exercise price per Pre-Funded Warrant. The closing of the private placement occurred on October 27, 2025 following the satisfaction of the closing conditions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrants are exercisable by the holder at any time on or after the closing date of the private placement until the tenth anniversary of such closing date, subject to a 9.99% beneficial ownership blocker. At any time during the last 90 days of the term of the Pre-Funded Warrants, the holder thereof may exchange a Pre-Funded Warrant with the Issuer for a new Pre-Funded Warrant to purchase the number of Pre-Funded Warrant Shares then remaining under such Pre-Funded Warrant, with a subsequent ten-year exercise period."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These reported securities are directly owned by RedCo II. Redmile Group, LLC (\"Redmile\") may be deemed to beneficially own the reported securities as the investment manager of RedCo II. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any. This report shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3846153,"derivative":{"exercise_date":"2025-10-27","underlying":"Common Share","underlying_shares":3846153},"source":{"system":"sec-edgar","filing":"0001104659-25-103336","document":"tm2529454-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465925103336/tm2529454-1_4seq1.xml","form_type":"4"}},{"id":1107863,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":30346,"kind":"person","name":"Squarer Ron","position":1,"cik":"0001454001","reported_name":"Squarer Ron","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-06-17T21:03:44.000Z","date":"2025-06-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":15184,"price":3.58,"value":54358.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":93627,"source":{"system":"sec-edgar","filing":"0001628280-25-031895","document":"wk-form4_1750194217.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454001/000162828025031895/wk-form4_1750194217.xml","form_type":"4"}},{"id":1107465,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":31980,"kind":"person","name":"Sandor Victor","position":1,"cik":"0001620368","reported_name":"Sandor Victor","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-06-17T21:03:18.000Z","date":"2025-06-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":12600,"price":3.58,"value":45108.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":108286,"source":{"system":"sec-edgar","filing":"0001628280-25-031894","document":"wk-form4_1750194190.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1620368/000162828025031894/wk-form4_1750194190.xml","form_type":"4"}},{"id":1107280,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":41602,"kind":"person","name":"Monges Viviane","position":1,"cik":"0001838204","reported_name":"Monges Viviane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-06-17T21:02:50.000Z","date":"2025-06-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":2584,"price":3.58,"value":9250.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":144043,"source":{"system":"sec-edgar","filing":"0001628280-25-031893","document":"wk-form4_1750194163.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1771910/000162828025031893/wk-form4_1750194163.xml","form_type":"4"}},{"id":1107456,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":37129,"kind":"person","name":"BIZZARI JEAN-PIERRE","position":1,"cik":"0001630914","reported_name":"BIZZARI JEAN-PIERRE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-06-17T21:00:55.000Z","date":"2025-06-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":12600,"price":3.58,"value":45108.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":106902,"source":{"system":"sec-edgar","filing":"0001628280-25-031891","document":"wk-form4_1750194047.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1630914/000162828025031891/wk-form4_1750194047.xml","form_type":"4"}},{"id":1107437,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-06-17T21:00:08.000Z","date":"2025-06-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":12600,"price":3.58,"value":45108.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":80405,"source":{"system":"sec-edgar","filing":"0001628280-25-031890","document":"wk-form4_1750193999.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656998/000162828025031890/wk-form4_1750193999.xml","form_type":"4"}},{"id":1108308,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":41821,"kind":"person","name":"Hug Peter","position":1,"cik":"0002000702","reported_name":"Hug Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-06-17T17:01:36.000Z","date":"2025-06-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":2144,"price":3.58,"value":7675.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":220500,"source":{"system":"sec-edgar","filing":"0001628280-25-031892","document":"wk-form4_1750194089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000702/000162828025031892/wk-form4_1750194089.xml","form_type":"4"}},{"id":1111428,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2025-06-13T22:00:54.000Z","date":"2025-06-11","kind":"purchase","planned":false,"acquired":true,"shares":12465234,"price":3.432,"value":42780683.088,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price of the Pre-Funded Warrants is CHF 0.08 per Pre-Funded Warrant Share. Based on the June 11, 2025 exchange rate of approximately US$1.219 to CHF 1.00, the exercise price of the Pre-Funded Warrants in US Dollars as of June 11, 2025 was approximately $0.098."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 11, 2025, certain private investment vehicles managed by Redmile Group, LLC (collectively, the \"Redmile Clients\"), including RedCo II Master Fund, L.P. (\"RedCo II\"), entered into a securities purchase agreement (the \"Purchase Agreement\") in connection with a private placement by the Issuer to certain institutional investors. Pursuant to the terms of the Purchase Agreement, the Redmile Clients will acquire 15,734,267 pre-funded warrants to purchase Common Shares (the \"Pre-Funded Warrants\") as of the closing date on June 16, 2025. The purchase price per Pre-Funded Warrant, excluding the exercise price (see footnote 2 below), is $3.432."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrants are exercisable by the holder at any time on or after the closing date of the private placement until the tenth anniversary of such closing date, subject to a 9.99% beneficial ownership blocker. At any time during the last 90 days of the term of the Pre-Funded Warrants, the holder thereof may exchange a Pre-Funded Warrant with the Issuer for a new Pre-Funded Warrant to purchase the number of Pre-Funded Warrant Shares then remaining under such Pre-Funded Warrant, with a subsequent ten-year exercise period."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Redmile Group, LLC (\"Redmile\") may be deemed to beneficially own the reported securities as the investment manager of the Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any. This report shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"These reported securities are directly owned by RedCo II and this transaction is a repetition of the same transaction disclosed in the row above to disclose this fund's direct ownership."}],"balance_after":12465234,"derivative":{"exercise_date":"2025-06-16","underlying":"Common Share","underlying_shares":12465234},"source":{"system":"sec-edgar","filing":"0001104659-25-059489","document":"tm2517929-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465925059489/tm2517929-1_4seq1.xml","form_type":"4"}},{"id":1111427,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2025-06-13T22:00:54.000Z","date":"2025-06-11","kind":"purchase","planned":false,"acquired":true,"shares":15734267,"price":3.432,"value":54000004.344,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price of the Pre-Funded Warrants is CHF 0.08 per Pre-Funded Warrant Share. Based on the June 11, 2025 exchange rate of approximately US$1.219 to CHF 1.00, the exercise price of the Pre-Funded Warrants in US Dollars as of June 11, 2025 was approximately $0.098."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 11, 2025, certain private investment vehicles managed by Redmile Group, LLC (collectively, the \"Redmile Clients\"), including RedCo II Master Fund, L.P. (\"RedCo II\"), entered into a securities purchase agreement (the \"Purchase Agreement\") in connection with a private placement by the Issuer to certain institutional investors. Pursuant to the terms of the Purchase Agreement, the Redmile Clients will acquire 15,734,267 pre-funded warrants to purchase Common Shares (the \"Pre-Funded Warrants\") as of the closing date on June 16, 2025. The purchase price per Pre-Funded Warrant, excluding the exercise price (see footnote 2 below), is $3.432."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrants are exercisable by the holder at any time on or after the closing date of the private placement until the tenth anniversary of such closing date, subject to a 9.99% beneficial ownership blocker. At any time during the last 90 days of the term of the Pre-Funded Warrants, the holder thereof may exchange a Pre-Funded Warrant with the Issuer for a new Pre-Funded Warrant to purchase the number of Pre-Funded Warrant Shares then remaining under such Pre-Funded Warrant, with a subsequent ten-year exercise period."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These reported securities are directly owned by the Redmile Clients, including RedCo II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Redmile Group, LLC (\"Redmile\") may be deemed to beneficially own the reported securities as the investment manager of the Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any. This report shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":15734267,"derivative":{"exercise_date":"2025-06-16","underlying":"Common Share","underlying_shares":15734267},"source":{"system":"sec-edgar","filing":"0001104659-25-059489","document":"tm2517929-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465925059489/tm2517929-1_4seq1.xml","form_type":"4"}},{"id":1120991,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":37659,"kind":"person","name":"Coughlin Timothy","position":1,"cik":"0001376043","reported_name":"COUGHLIN TIMOTHY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2025-06-05T21:13:04.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents a one-time initial stock option award made under the Issuer's 2019 Equity Incentive Plan. The options vest over four years from June 3, 2025, with 1/4 vesting on the first anniversary of such date, and the remainder vesting monthly in 36 equal installments, subject to continued service through each such vesting date."}],"balance_after":80000,"derivative":{"exercise_price":3.59,"expiration_date":"2035-06-05","underlying":"Common Shares","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001628280-25-029742","document":"wk-form4_1749157954.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1376043/000162828025029742/wk-form4_1749157954.xml","form_type":"4"}},{"id":1120990,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":37659,"kind":"person","name":"Coughlin Timothy","position":1,"cik":"0001376043","reported_name":"COUGHLIN TIMOTHY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-06-05T21:13:04.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the annual grant of restricted stock units (\"RSUs\") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest one year from the grant date, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001628280-25-029742","document":"wk-form4_1749157954.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1376043/000162828025029742/wk-form4_1749157954.xml","form_type":"4"}},{"id":1120886,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":31980,"kind":"person","name":"Sandor Victor","position":1,"cik":"0001620368","reported_name":"Sandor Victor","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-06-05T21:12:04.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the annual grant of restricted stock units (\"RSUs\") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest one year from the grant date, subject to the Reporting Person's\ncontinued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":120886,"source":{"system":"sec-edgar","filing":"0001628280-25-029739","document":"wk-form4_1749157895.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1620368/000162828025029739/wk-form4_1749157895.xml","form_type":"4"}},{"id":1120876,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-06-05T21:10:51.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the annual grant of restricted stock units (\"RSUs\") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest one year from the grant date, subject to the Reporting Person's\ncontinued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":93005,"source":{"system":"sec-edgar","filing":"0001628280-25-029736","document":"wk-form4_1749157790.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656998/000162828025029736/wk-form4_1749157790.xml","form_type":"4"}},{"id":1120881,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":37129,"kind":"person","name":"BIZZARI JEAN-PIERRE","position":1,"cik":"0001630914","reported_name":"BIZZARI JEAN-PIERRE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-06-05T21:09:17.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the annual grant of restricted stock units (\"RSUs\") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest one year from the grant date, subject to the Reporting Person's\ncontinued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":119502,"source":{"system":"sec-edgar","filing":"0001628280-25-029735","document":"wk-form4_1749157731.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1630914/000162828025029735/wk-form4_1749157731.xml","form_type":"4"}},{"id":1120845,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":41602,"kind":"person","name":"Monges Viviane","position":1,"cik":"0001838204","reported_name":"Monges Viviane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-06-05T21:07:08.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the annual grant of restricted stock units (\"RSUs\") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest one year from the grant date, subject to the Reporting Person's\ncontinued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":146627,"source":{"system":"sec-edgar","filing":"0001628280-25-029729","document":"wk-form4_1749157579.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1771910/000162828025029729/wk-form4_1749157579.xml","form_type":"4"}},{"id":1121227,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":30346,"kind":"person","name":"Squarer Ron","position":1,"cik":"0001454001","reported_name":"Squarer Ron","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-06-05T21:05:59.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the annual grant of restricted stock units (\"RSUs\") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest one year from the grant date, subject to the Reporting Person's\ncontinued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":108811,"source":{"system":"sec-edgar","filing":"0001628280-25-029724","document":"wk-form4_1749157450.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454001/000162828025029724/wk-form4_1749157450.xml","form_type":"4"}},{"id":1121623,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":41821,"kind":"person","name":"Hug Peter","position":1,"cik":"0002000702","reported_name":"Hug Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-06-05T17:08:22.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the annual grant of restricted stock units (\"RSUs\") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest one year from the grant date, subject to the Reporting Person's\ncontinued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":222644,"source":{"system":"sec-edgar","filing":"0001628280-25-029733","document":"wk-form4_1749157641.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000702/000162828025029733/wk-form4_1749157641.xml","form_type":"4"}},{"id":1141727,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":79578,"kind":"person","name":"Pfisterer Thomas","position":1,"cik":"0001824238","reported_name":"Pfisterer Thomas","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanations"}}],"security":"Common Shares","published_at":"2025-05-19T19:35:33.000Z","date":"2025-05-15","kind":"other","planned":false,"acquired":false,"shares":451856,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In addition to the 173,899 shares still owned by Thomas Pfisterer, he previously held 451,856 shares directly or indirectly via HPWH MH AG (\"MH\") and HPWH TH AG (\"HPWH\") but following stepping down from the Board of Directors of MH and HPWH transferred ownership by way of an intragroup sale to Dr. Hans-Peter Wild."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In addition to the 173,899 shares still owned by Thomas Pfisterer, he previously held 451,856 shares directly or indirectly via HPWH MH AG (\"MH\") and HPWH TH AG (\"HPWH\") but following stepping down from the Board of Directors of MH and HPWH transferred ownership by way of an intragroup sale to Dr. Hans-Peter Wild."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"In addition to the 173,899 shares still owned by Thomas Pfisterer, he previously held 451,856 shares directly or indirectly via HPWH MH AG (\"MH\") and HPWH TH AG (\"HPWH\") but following stepping down from the Board of Directors of MH and HPWH transferred ownership by way of an intragroup sale to Dr. Hans-Peter Wild."}],"balance_after":173899,"source":{"system":"sec-edgar","filing":"0001731122-25-000777","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1771910/000173112225000777/ownership.xml","form_type":"4"}},{"id":1143814,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":79643,"kind":"person","name":"WILD HANS PETER","position":1,"cik":"0000905538","reported_name":"WILD HANS PETER","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2025-05-19T15:52:01.000Z","date":"2025-05-15","kind":"other","planned":false,"acquired":true,"shares":9788944,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Dr. Hans-Peter Wild (\"Dr. Wild\") holds a portion of the shares directly and another portion indirectly via HP Wild Holding AG (\"HPW Holding\") and HPWH TH AG (\"HPWH\"). The principal business of HPWH is holding investment rights in, directly or indirectly, ADCT. HPW Holding is an intermediary holding company and Dr. Wild is the Chairman of HPW Holding and HPWH. Thomas Pfisterer was a member of the Board of HPWH and held a total of 451,856 shares directly or indirectly in HPWH, but has transferred such ownership by way of an intragroup sale following Thomas Pfisterer stepping down from the Board of HPWH."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Dr. Hans-Peter Wild (\"Dr. Wild\") holds a portion of the shares directly and another portion indirectly via HP Wild Holding AG (\"HPW Holding\") and HPWH TH AG (\"HPWH\"). The principal business of HPWH is holding investment rights in, directly or indirectly, ADCT. HPW Holding is an intermediary holding company and Dr. Wild is the Chairman of HPW Holding and HPWH. Thomas Pfisterer was a member of the Board of HPWH and held a total of 451,856 shares directly or indirectly in HPWH, but has transferred such ownership by way of an intragroup sale following Thomas Pfisterer stepping down from the Board of HPWH."}],"balance_after":9788944,"source":{"system":"sec-edgar","filing":"0001731122-25-000779","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/905538/000173112225000779/ownership.xml","form_type":"4"}},{"id":1155175,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":32949,"kind":"person","name":"MALLIK AMEET","position":1,"cik":"0001861441","reported_name":"MALLIK AMEET","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2025-05-09T01:14:46.000Z","date":"2025-05-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":26758,"price":1.29,"value":34517.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":1552247,"source":{"system":"sec-edgar","filing":"0001628280-25-024021","document":"wk-form4_1746753278.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861441/000162828025024021/wk-form4_1746753278.xml","form_type":"4"}},{"id":1266942,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2025-02-14T23:23:22.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":220000,"price":1.61,"value":354200.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Common Shares to be delivered in settlement of a restricted share unit award which vests one-third on the first anniversary of the grant date, which grant date is February 13, 2025, and then one-third on each anniversary date thereafter, upon continued service through the designated vesting event."}],"balance_after":408542,"source":{"system":"sec-edgar","filing":"0001628280-25-005863","document":"wk-form4_1739575395.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235635/000162828025005863/wk-form4_1739575395.xml","form_type":"4"}},{"id":1267688,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":33006,"kind":"person","name":"Zaki Mohamed","position":1,"cik":"0002000697","reported_name":"Zaki Mohamed","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2025-02-14T23:22:49.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":230000,"price":1.61,"value":370300.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Common Shares to be delivered in settlement of a restricted share unit award which vests one-third on the first anniversary of the grant date, which grant date is February 13, 2025, and then one-third on each anniversary date thereafter, upon continued service through the designated vesting event."}],"balance_after":462888,"source":{"system":"sec-edgar","filing":"0001628280-25-005862","document":"wk-form4_1739575362.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000697/000162828025005862/wk-form4_1739575362.xml","form_type":"4"}},{"id":1267336,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":32873,"kind":"person","name":"Carmona Jose","position":1,"cik":"0001693612","reported_name":"Carmona Jose","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2025-02-14T23:21:42.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":240000,"price":1.61,"value":386400.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Common Shares to be delivered in settlement of a restricted share unit award which vests one-third on the first anniversary of the grant date, which grant date is February 13, 2025, and then one-third on each anniversary date thereafter, upon continued service through the designated vesting event."}],"balance_after":541892,"source":{"system":"sec-edgar","filing":"0001628280-25-005860","document":"wk-form4_1739575294.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693612/000162828025005860/wk-form4_1739575294.xml","form_type":"4"}},{"id":1267570,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":32949,"kind":"person","name":"MALLIK AMEET","position":1,"cik":"0001861441","reported_name":"MALLIK AMEET","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2025-02-14T23:20:59.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":650000,"price":1.61,"value":1046500.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Common Shares to be delivered in settlement of a restricted share unit award which vests one-third on the first anniversary of the grant date, which grant date is February 13, 2025, and then one-third on each anniversary date thereafter, upon continued service through the designated vesting event."}],"balance_after":1579005,"source":{"system":"sec-edgar","filing":"0001628280-25-005859","document":"wk-form4_1739575251.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861441/000162828025005859/wk-form4_1739575251.xml","form_type":"4"}},{"id":1267687,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":65933,"kind":"person","name":"Kallebo Lisa Michelle","position":1,"cik":"0002000724","reported_name":"Kallebo Lisa Michelle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2025-02-14T18:22:17.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":41900,"price":1.61,"value":67459.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Common Shares to be delivered in settlement of a restricted share unit award which vests one-third on the first anniversary of the grant date, which grant date is February 13, 2025, and then one-third on each anniversary date thereafter, upon continued service through the designated vesting event."}],"balance_after":77897,"source":{"system":"sec-edgar","filing":"0001628280-25-005861","document":"wk-form4_1739575330.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000724/000162828025005861/wk-form4_1739575330.xml","form_type":"4"}},{"id":1332215,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value CHF 0.08 per share","published_at":"2024-12-14T02:00:14.000Z","date":"2024-12-11","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":3.81,"value":190500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.64 to $3.9, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Redmile may be deemed to beneficially own the reported securities as the investment manager of the Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green (collectively with RedCo II, the \"Reporting Persons\") disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"These securities are directly owned by RedCo II and this transaction is a repetition of the same transaction disclosed in the row above to disclose this fund's direct ownership."}],"balance_after":13145712,"source":{"system":"sec-edgar","filing":"0001104659-24-128575","document":"tm2431001-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465924128575/tm2431001-1_4seq1.xml","form_type":"4"}},{"id":1332214,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value CHF 0.08 per share","published_at":"2024-12-14T02:00:14.000Z","date":"2024-12-11","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":2.28,"value":114000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.165 to $2.4, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Redmile may be deemed to beneficially own the reported securities as the investment manager of the Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green (collectively with RedCo II, the \"Reporting Persons\") disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"These securities are directly owned by RedCo II and this transaction is a repetition of the same transaction disclosed in the row above to disclose this fund's direct ownership."}],"balance_after":13095712,"source":{"system":"sec-edgar","filing":"0001104659-24-128575","document":"tm2431001-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465924128575/tm2431001-1_4seq1.xml","form_type":"4"}},{"id":1332213,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value CHF 0.08 per share","published_at":"2024-12-14T02:00:14.000Z","date":"2024-12-11","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":3.81,"value":190500.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.64 to $3.9, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These reported securities are directly owned by private investment vehicles managed by Redmile Group, LLC (\"Redmile\"), including RedCo II Master Fund, L.P. (collectively, the \"Redmile Clients\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Redmile may be deemed to beneficially own the reported securities as the investment manager of the Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green (collectively with RedCo II, the \"Reporting Persons\") disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":15666731,"source":{"system":"sec-edgar","filing":"0001104659-24-128575","document":"tm2431001-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465924128575/tm2431001-1_4seq1.xml","form_type":"4"}},{"id":1332212,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value CHF 0.08 per share","published_at":"2024-12-14T02:00:14.000Z","date":"2024-12-11","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":2.28,"value":114000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.165 to $2.4, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These reported securities are directly owned by private investment vehicles managed by Redmile Group, LLC (\"Redmile\"), including RedCo II Master Fund, L.P. (collectively, the \"Redmile Clients\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Redmile may be deemed to beneficially own the reported securities as the investment manager of the Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green (collectively with RedCo II, the \"Reporting Persons\") disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":15616731,"source":{"system":"sec-edgar","filing":"0001104659-24-128575","document":"tm2431001-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465924128575/tm2431001-1_4seq1.xml","form_type":"4"}},{"id":1339242,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":33006,"kind":"person","name":"Zaki Mohamed","position":1,"cik":"0002000697","reported_name":"Zaki Mohamed","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2024-12-10T01:42:48.000Z","date":"2024-12-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":37112,"price":3.13,"value":116160.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":232888,"source":{"system":"sec-edgar","filing":"0001628280-24-050543","document":"wk-form4_1733794961.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000697/000162828024050543/wk-form4_1733794961.xml","form_type":"4"}},{"id":1339049,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":32873,"kind":"person","name":"Carmona Jose","position":1,"cik":"0001693612","reported_name":"Carmona Jose","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2024-12-10T01:37:39.000Z","date":"2024-12-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":48108,"price":3.13,"value":150578.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":301892,"source":{"system":"sec-edgar","filing":"0001628280-24-050541","document":"wk-form4_1733794651.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693612/000162828024050541/wk-form4_1733794651.xml","form_type":"4"}},{"id":1338817,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2024-12-10T01:35:22.000Z","date":"2024-12-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":41458,"price":3.13,"value":129763.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":188542,"source":{"system":"sec-edgar","filing":"0001628280-24-050540","document":"wk-form4_1733794514.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235635/000162828024050540/wk-form4_1733794514.xml","form_type":"4"}},{"id":1339161,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":32949,"kind":"person","name":"MALLIK AMEET","position":1,"cik":"0001861441","reported_name":"MALLIK AMEET","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2024-12-10T01:30:25.000Z","date":"2024-12-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":238343,"price":3.13,"value":746013.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":929005,"source":{"system":"sec-edgar","filing":"0001628280-24-050539","document":"wk-form4_1733794216.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861441/000162828024050539/wk-form4_1733794216.xml","form_type":"4"}},{"id":1339239,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":65933,"kind":"person","name":"Kallebo Lisa Michelle","position":1,"cik":"0002000724","reported_name":"Kallebo Lisa Michelle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2024-12-09T20:39:33.000Z","date":"2024-12-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":6503,"price":3.13,"value":20354.39,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":35997,"source":{"system":"sec-edgar","filing":"0001628280-24-050542","document":"wk-form4_1733794766.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000724/000162828024050542/wk-form4_1733794766.xml","form_type":"4"}},{"id":1340325,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2024-12-07T02:00:37.000Z","date":"2024-12-04","kind":"other","planned":false,"acquired":true,"shares":26656,"price":2.07,"value":55177.92,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The exercise price of the Pre-Funded Warrants is CHF 0.08 per Pre-Funded Warrant Share. Based on the December 4, 2024 exchange rate of $1.13 USD to CHF 1.00, the exercise price of the Pre-Funded Warrants in US Dollars as of December 4, 2024 is approximately $0.09."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 4, 2024, certain private investment vehicles managed by Redmile Group, LLC (\"Redmile\"), including RedCo II Master Fund, L.P. (\"RedCo II\" and collectively with the other private investment vehicles managed by Redmile, the \"Redmile Clients\"), engaged in cross trades with respect to 50,672 Common Shares and 26,656 pre-funded warrants to purchase Common Shares (the \"Pre-Funded Warrants\"). A Redmile Client also sold an additional 25,352 Common Shares concurrently with the cross trades at the same price. The reported transactions occurred simultaneously, at which time the price per share of the Common Shares was $2.07 (or $1.98 for the Pre-Funded Warrants, which excludes the exercise price, see footnote 6 below), and therefore the reported transactions resulted in no profit to Redmile or Jeremy Green and the cross trades resulted in no change in either of their aggregate beneficial ownership."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 4, 2024, certain private investment vehicles managed by Redmile Group, LLC (\"Redmile\"), including RedCo II Master Fund, L.P. (\"RedCo II\" and collectively with the other private investment vehicles managed by Redmile, the \"Redmile Clients\"), engaged in cross trades with respect to 50,672 Common Shares and 26,656 pre-funded warrants to purchase Common Shares (the \"Pre-Funded Warrants\"). A Redmile Client also sold an additional 25,352 Common Shares concurrently with the cross trades at the same price. The reported transactions occurred simultaneously, at which time the price per share of the Common Shares was $2.07 (or $1.98 for the Pre-Funded Warrants, which excludes the exercise price, see footnote 6 below), and therefore the reported transactions resulted in no profit to Redmile or Jeremy Green and the cross trades resulted in no change in either of their aggregate beneficial ownership."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Pre-Funded Warrants are exercisable by the holder at any time after their original issuance until the tenth anniversary of their original issuance, subject to a 9.99% beneficial ownership blocker. At any time during the last 90 days of the term of the Pre-Funded Warrants, the holder thereof may exchange a Pre Funded Warrant with the Issuer for a new Pre-Funded Warrant to purchase the number of Pre-Funded Warrant Shares then remaining under such Pre-Funded Warrant, with a subsequent ten-year exercise period."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Redmile may be deemed to beneficially own the reported securities as the investment manager of the Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green (collectively with RedCo II, the \"Reporting Persons\") disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"These securities are directly owned by RedCo II and this transaction is a repetition of the same transaction disclosed in the row immediately above to disclose this fund's direct ownership."}],"balance_after":6133837,"derivative":{"exercise_date":"2024-05-08","underlying":"Common Shares","underlying_shares":26656},"source":{"system":"sec-edgar","filing":"0001104659-24-126422","document":"tm2430300-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465924126422/tm2430300-1_4seq1.xml","form_type":"4"}},{"id":1340324,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2024-12-07T02:00:37.000Z","date":"2024-12-04","kind":"other","planned":false,"acquired":true,"shares":26656,"price":2.07,"value":55177.92,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The exercise price of the Pre-Funded Warrants is CHF 0.08 per Pre-Funded Warrant Share. Based on the December 4, 2024 exchange rate of $1.13 USD to CHF 1.00, the exercise price of the Pre-Funded Warrants in US Dollars as of December 4, 2024 is approximately $0.09."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 4, 2024, certain private investment vehicles managed by Redmile Group, LLC (\"Redmile\"), including RedCo II Master Fund, L.P. (\"RedCo II\" and collectively with the other private investment vehicles managed by Redmile, the \"Redmile Clients\"), engaged in cross trades with respect to 50,672 Common Shares and 26,656 pre-funded warrants to purchase Common Shares (the \"Pre-Funded Warrants\"). A Redmile Client also sold an additional 25,352 Common Shares concurrently with the cross trades at the same price. The reported transactions occurred simultaneously, at which time the price per share of the Common Shares was $2.07 (or $1.98 for the Pre-Funded Warrants, which excludes the exercise price, see footnote 6 below), and therefore the reported transactions resulted in no profit to Redmile or Jeremy Green and the cross trades resulted in no change in either of their aggregate beneficial ownership."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 4, 2024, certain private investment vehicles managed by Redmile Group, LLC (\"Redmile\"), including RedCo II Master Fund, L.P. (\"RedCo II\" and collectively with the other private investment vehicles managed by Redmile, the \"Redmile Clients\"), engaged in cross trades with respect to 50,672 Common Shares and 26,656 pre-funded warrants to purchase Common Shares (the \"Pre-Funded Warrants\"). A Redmile Client also sold an additional 25,352 Common Shares concurrently with the cross trades at the same price. The reported transactions occurred simultaneously, at which time the price per share of the Common Shares was $2.07 (or $1.98 for the Pre-Funded Warrants, which excludes the exercise price, see footnote 6 below), and therefore the reported transactions resulted in no profit to Redmile or Jeremy Green and the cross trades resulted in no change in either of their aggregate beneficial ownership."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Pre-Funded Warrants are exercisable by the holder at any time after their original issuance until the tenth anniversary of their original issuance, subject to a 9.99% beneficial ownership blocker. At any time during the last 90 days of the term of the Pre-Funded Warrants, the holder thereof may exchange a Pre Funded Warrant with the Issuer for a new Pre-Funded Warrant to purchase the number of Pre-Funded Warrant Shares then remaining under such Pre-Funded Warrant, with a subsequent ten-year exercise period."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These reported securities are directly owned by the Redmile Clients."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Redmile may be deemed to beneficially own the reported securities as the investment manager of the Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green (collectively with RedCo II, the \"Reporting Persons\") disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":8163265,"derivative":{"exercise_date":"2024-05-08","underlying":"Common Shares","underlying_shares":26656},"source":{"system":"sec-edgar","filing":"0001104659-24-126422","document":"tm2430300-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465924126422/tm2430300-1_4seq1.xml","form_type":"4"}},{"id":1340323,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2024-12-07T02:00:37.000Z","date":"2024-12-04","kind":"other","planned":false,"acquired":false,"shares":26656,"price":2.07,"value":55177.92,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The exercise price of the Pre-Funded Warrants is CHF 0.08 per Pre-Funded Warrant Share. Based on the December 4, 2024 exchange rate of $1.13 USD to CHF 1.00, the exercise price of the Pre-Funded Warrants in US Dollars as of December 4, 2024 is approximately $0.09."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 4, 2024, certain private investment vehicles managed by Redmile Group, LLC (\"Redmile\"), including RedCo II Master Fund, L.P. (\"RedCo II\" and collectively with the other private investment vehicles managed by Redmile, the \"Redmile Clients\"), engaged in cross trades with respect to 50,672 Common Shares and 26,656 pre-funded warrants to purchase Common Shares (the \"Pre-Funded Warrants\"). A Redmile Client also sold an additional 25,352 Common Shares concurrently with the cross trades at the same price. The reported transactions occurred simultaneously, at which time the price per share of the Common Shares was $2.07 (or $1.98 for the Pre-Funded Warrants, which excludes the exercise price, see footnote 6 below), and therefore the reported transactions resulted in no profit to Redmile or Jeremy Green and the cross trades resulted in no change in either of their aggregate beneficial ownership."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 4, 2024, certain private investment vehicles managed by Redmile Group, LLC (\"Redmile\"), including RedCo II Master Fund, L.P. (\"RedCo II\" and collectively with the other private investment vehicles managed by Redmile, the \"Redmile Clients\"), engaged in cross trades with respect to 50,672 Common Shares and 26,656 pre-funded warrants to purchase Common Shares (the \"Pre-Funded Warrants\"). A Redmile Client also sold an additional 25,352 Common Shares concurrently with the cross trades at the same price. The reported transactions occurred simultaneously, at which time the price per share of the Common Shares was $2.07 (or $1.98 for the Pre-Funded Warrants, which excludes the exercise price, see footnote 6 below), and therefore the reported transactions resulted in no profit to Redmile or Jeremy Green and the cross trades resulted in no change in either of their aggregate beneficial ownership."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Pre-Funded Warrants are exercisable by the holder at any time after their original issuance until the tenth anniversary of their original issuance, subject to a 9.99% beneficial ownership blocker. At any time during the last 90 days of the term of the Pre-Funded Warrants, the holder thereof may exchange a Pre Funded Warrant with the Issuer for a new Pre-Funded Warrant to purchase the number of Pre-Funded Warrant Shares then remaining under such Pre-Funded Warrant, with a subsequent ten-year exercise period."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These reported securities are directly owned by the Redmile Clients."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Redmile may be deemed to beneficially own the reported securities as the investment manager of the Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green (collectively with RedCo II, the \"Reporting Persons\") disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":8136609,"derivative":{"exercise_date":"2024-05-08","underlying":"Common Shares","underlying_shares":26656},"source":{"system":"sec-edgar","filing":"0001104659-24-126422","document":"tm2430300-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465924126422/tm2430300-1_4seq1.xml","form_type":"4"}},{"id":1340322,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value CHF 0.08 per share","published_at":"2024-12-07T02:00:37.000Z","date":"2024-12-04","kind":"other","planned":false,"acquired":true,"shares":50672,"price":2.07,"value":104891.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 4, 2024, certain private investment vehicles managed by Redmile Group, LLC (\"Redmile\"), including RedCo II Master Fund, L.P. (\"RedCo II\" and collectively with the other private investment vehicles managed by Redmile, the \"Redmile Clients\"), engaged in cross trades with respect to 50,672 Common Shares and 26,656 pre-funded warrants to purchase Common Shares (the \"Pre-Funded Warrants\"). A Redmile Client also sold an additional 25,352 Common Shares concurrently with the cross trades at the same price. The reported transactions occurred simultaneously, at which time the price per share of the Common Shares was $2.07 (or $1.98 for the Pre-Funded Warrants, which excludes the exercise price, see footnote 6 below), and therefore the reported transactions resulted in no profit to Redmile or Jeremy Green and the cross trades resulted in no change in either of their aggregate beneficial ownership."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Redmile may be deemed to beneficially own the reported securities as the investment manager of the Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green (collectively with RedCo II, the \"Reporting Persons\") disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"These securities are directly owned by RedCo II and this transaction is a repetition of the same transaction disclosed in the row immediately above to disclose this fund's direct ownership."}],"balance_after":13045712,"source":{"system":"sec-edgar","filing":"0001104659-24-126422","document":"tm2430300-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465924126422/tm2430300-1_4seq1.xml","form_type":"4"}},{"id":1340321,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value CHF 0.08 per share","published_at":"2024-12-07T02:00:37.000Z","date":"2024-12-04","kind":"other","planned":false,"acquired":true,"shares":50672,"price":2.07,"value":104891.04,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 4, 2024, certain private investment vehicles managed by Redmile Group, LLC (\"Redmile\"), including RedCo II Master Fund, L.P. (\"RedCo II\" and collectively with the other private investment vehicles managed by Redmile, the \"Redmile Clients\"), engaged in cross trades with respect to 50,672 Common Shares and 26,656 pre-funded warrants to purchase Common Shares (the \"Pre-Funded Warrants\"). A Redmile Client also sold an additional 25,352 Common Shares concurrently with the cross trades at the same price. The reported transactions occurred simultaneously, at which time the price per share of the Common Shares was $2.07 (or $1.98 for the Pre-Funded Warrants, which excludes the exercise price, see footnote 6 below), and therefore the reported transactions resulted in no profit to Redmile or Jeremy Green and the cross trades resulted in no change in either of their aggregate beneficial ownership."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These reported securities are directly owned by the Redmile Clients."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Redmile may be deemed to beneficially own the reported securities as the investment manager of the Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green (collectively with RedCo II, the \"Reporting Persons\") disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":15566731,"source":{"system":"sec-edgar","filing":"0001104659-24-126422","document":"tm2430300-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465924126422/tm2430300-1_4seq1.xml","form_type":"4"}},{"id":1340320,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value CHF 0.08 per share","published_at":"2024-12-07T02:00:37.000Z","date":"2024-12-04","kind":"other","planned":false,"acquired":false,"shares":50672,"price":2.07,"value":104891.04,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 4, 2024, certain private investment vehicles managed by Redmile Group, LLC (\"Redmile\"), including RedCo II Master Fund, L.P. (\"RedCo II\" and collectively with the other private investment vehicles managed by Redmile, the \"Redmile Clients\"), engaged in cross trades with respect to 50,672 Common Shares and 26,656 pre-funded warrants to purchase Common Shares (the \"Pre-Funded Warrants\"). A Redmile Client also sold an additional 25,352 Common Shares concurrently with the cross trades at the same price. The reported transactions occurred simultaneously, at which time the price per share of the Common Shares was $2.07 (or $1.98 for the Pre-Funded Warrants, which excludes the exercise price, see footnote 6 below), and therefore the reported transactions resulted in no profit to Redmile or Jeremy Green and the cross trades resulted in no change in either of their aggregate beneficial ownership."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These reported securities are directly owned by the Redmile Clients."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Redmile may be deemed to beneficially own the reported securities as the investment manager of the Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green (collectively with RedCo II, the \"Reporting Persons\") disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":15516059,"source":{"system":"sec-edgar","filing":"0001104659-24-126422","document":"tm2430300-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465924126422/tm2430300-1_4seq1.xml","form_type":"4"}},{"id":1340319,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value CHF 0.08 per share","published_at":"2024-12-07T02:00:37.000Z","date":"2024-12-04","kind":"sale","planned":false,"acquired":false,"shares":25352,"price":2.07,"value":52478.64,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 4, 2024, certain private investment vehicles managed by Redmile Group, LLC (\"Redmile\"), including RedCo II Master Fund, L.P. (\"RedCo II\" and collectively with the other private investment vehicles managed by Redmile, the \"Redmile Clients\"), engaged in cross trades with respect to 50,672 Common Shares and 26,656 pre-funded warrants to purchase Common Shares (the \"Pre-Funded Warrants\"). A Redmile Client also sold an additional 25,352 Common Shares concurrently with the cross trades at the same price. The reported transactions occurred simultaneously, at which time the price per share of the Common Shares was $2.07 (or $1.98 for the Pre-Funded Warrants, which excludes the exercise price, see footnote 6 below), and therefore the reported transactions resulted in no profit to Redmile or Jeremy Green and the cross trades resulted in no change in either of their aggregate beneficial ownership."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Since the last Form 4 filing by Redmile and Mr. Green, Redmile has ceased serving as the investment adviser to a sub-advised account that held 77,134 shares of the Issuer's Common Shares (such shares, the \"Account Shares\") and therefore no longer has voting or dispositive power with respect to such shares. Accordingly, the amount of shares beneficially owned by Redmile and Mr. Green as disclosed herein does not include the Account Shares and each of Redmile and Mr. Green disclaims beneficial ownership of the Account Shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These reported securities are directly owned by the Redmile Clients."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Redmile may be deemed to beneficially own the reported securities as the investment manager of the Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green (collectively with RedCo II, the \"Reporting Persons\") disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":15566731,"source":{"system":"sec-edgar","filing":"0001104659-24-126422","document":"tm2430300-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465924126422/tm2430300-1_4seq1.xml","form_type":"4"}},{"id":1459742,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value CHF 0.08 per share","published_at":"2024-07-04T00:00:13.000Z","date":"2024-07-01","kind":"purchase","planned":false,"acquired":true,"shares":400000,"price":2.81,"value":1124000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green (collectively with RedCo II, the \"Reporting Persons\") disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These securities are directly owned by RedCo II and this transaction is a repetition of the same transaction disclosed above in the first row to disclose this fund's direct ownership."}],"balance_after":12995040,"source":{"system":"sec-edgar","filing":"0001104659-24-077865","document":"tm2418671-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465924077865/tm2418671-3_4seq1.xml","form_type":"4"}},{"id":1459741,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value CHF 0.08 per share","published_at":"2024-07-04T00:00:13.000Z","date":"2024-07-01","kind":"purchase","planned":false,"acquired":true,"shares":400000,"price":2.81,"value":1124000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are directly owned by certain private investment vehicles and sub-advised accounts managed by Redmile Group, LLC (\"Redmile\"), including RedCo II Master Fund, L.P. (\"RedCo II\" and collectively with the other private investment vehicles and sub-advised accounts managed by Redmile, the \"Redmile Clients\"). Redmile may be deemed to beneficially own the reported securities as investment manager of the Redmile Clients."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green (collectively with RedCo II, the \"Reporting Persons\") disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":15669217,"source":{"system":"sec-edgar","filing":"0001104659-24-077865","document":"tm2418671-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465924077865/tm2418671-3_4seq1.xml","form_type":"4"}},{"id":1474541,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-06-19T01:45:33.000Z","date":"2024-06-17","kind":"sale","planned":false,"acquired":false,"shares":6995,"price":2.89,"value":20215.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents Common Shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units."}],"balance_after":53005,"source":{"system":"sec-edgar","filing":"0001628280-24-028993","document":"wk-form4_1718761526.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656998/000162828024028993/wk-form4_1718761526.xml","form_type":"4"}},{"id":1474575,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":37129,"kind":"person","name":"BIZZARI JEAN-PIERRE","position":1,"cik":"0001630914","reported_name":"BIZZARI JEAN-PIERRE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-06-19T01:43:50.000Z","date":"2024-06-17","kind":"sale","planned":false,"acquired":false,"shares":6995,"price":2.89,"value":20215.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents Common Shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units."}],"balance_after":79502,"source":{"system":"sec-edgar","filing":"0001628280-24-028992","document":"wk-form4_1718761422.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1630914/000162828024028992/wk-form4_1718761422.xml","form_type":"4"}},{"id":1474396,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":41602,"kind":"person","name":"Monges Viviane","position":1,"cik":"0001838204","reported_name":"Monges Viviane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-06-19T01:40:13.000Z","date":"2024-06-17","kind":"sale","planned":false,"acquired":false,"shares":1437,"price":2.89,"value":4152.93,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents Common Shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units."}],"balance_after":106627,"source":{"system":"sec-edgar","filing":"0001628280-24-028990","document":"wk-form4_1718761205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1771910/000162828024028990/wk-form4_1718761205.xml","form_type":"4"}},{"id":1474395,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":79578,"kind":"person","name":"Pfisterer Thomas","position":1,"cik":"0001824238","reported_name":"Pfisterer Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-06-19T01:38:42.000Z","date":"2024-06-17","kind":"sale","planned":false,"acquired":false,"shares":1437,"price":2.89,"value":4152.93,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents Common Shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units."}],"balance_after":213900,"source":{"system":"sec-edgar","filing":"0001628280-24-028989","document":"wk-form4_1718761112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1771910/000162828024028989/wk-form4_1718761112.xml","form_type":"4"}},{"id":1474582,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":31980,"kind":"person","name":"Sandor Victor","position":1,"cik":"0001620368","reported_name":"Sandor Victor","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-06-19T01:37:20.000Z","date":"2024-06-17","kind":"sale","planned":false,"acquired":false,"shares":6995,"price":2.89,"value":20215.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents Common Shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units."}],"balance_after":80886,"source":{"system":"sec-edgar","filing":"0001628280-24-028988","document":"wk-form4_1718761032.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1620368/000162828024028988/wk-form4_1718761032.xml","form_type":"4"}},{"id":1475120,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":30346,"kind":"person","name":"Squarer Ron","position":1,"cik":"0001454001","reported_name":"Squarer Ron","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-06-19T01:35:24.000Z","date":"2024-06-17","kind":"sale","planned":false,"acquired":false,"shares":6995,"price":2.89,"value":20215.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents Common Shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units."}],"balance_after":80663,"source":{"system":"sec-edgar","filing":"0001628280-24-028987","document":"wk-form4_1718760917.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454001/000162828024028987/wk-form4_1718760917.xml","form_type":"4"}},{"id":1475815,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":41821,"kind":"person","name":"Hug Peter","position":1,"cik":"0002000702","reported_name":"Hug Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-06-18T21:41:51.000Z","date":"2024-06-17","kind":"sale","planned":false,"acquired":false,"shares":1193,"price":2.89,"value":3447.77,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents Common Shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units."}],"balance_after":182644,"source":{"system":"sec-edgar","filing":"0001628280-24-028991","document":"wk-form4_1718761304.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000702/000162828024028991/wk-form4_1718761304.xml","form_type":"4"}},{"id":1478450,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-06-14T21:46:59.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the annual grant of restricted stock units (\"RSUs\") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest one year from the grant date, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":60000,"source":{"system":"sec-edgar","filing":"0001628280-24-028357","document":"wk-form4_1718401609.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656998/000162828024028357/wk-form4_1718401609.xml","form_type":"4"}},{"id":1478462,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":37129,"kind":"person","name":"BIZZARI JEAN-PIERRE","position":1,"cik":"0001630914","reported_name":"BIZZARI JEAN-PIERRE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-06-14T21:44:32.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the annual grant of restricted stock units (\"RSUs\") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest one year from the grant date, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":86497,"source":{"system":"sec-edgar","filing":"0001628280-24-028355","document":"wk-form4_1718401463.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1630914/000162828024028355/wk-form4_1718401463.xml","form_type":"4"}},{"id":1478393,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":79578,"kind":"person","name":"Pfisterer Thomas","position":1,"cik":"0001824238","reported_name":"Pfisterer Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-06-14T21:37:11.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the annual grant of restricted stock units (\"RSUs\") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest one year from the grant date, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":215337,"source":{"system":"sec-edgar","filing":"0001628280-24-028351","document":"wk-form4_1718401022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1771910/000162828024028351/wk-form4_1718401022.xml","form_type":"4"}},{"id":1478463,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":31980,"kind":"person","name":"Sandor Victor","position":1,"cik":"0001620368","reported_name":"Sandor Victor","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-06-14T21:29:35.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the annual grant of restricted stock units (\"RSUs\") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest one year from the grant date, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":87881,"source":{"system":"sec-edgar","filing":"0001628280-24-028347","document":"wk-form4_1718400565.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1620368/000162828024028347/wk-form4_1718400565.xml","form_type":"4"}},{"id":1478879,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":30346,"kind":"person","name":"Squarer Ron","position":1,"cik":"0001454001","reported_name":"Squarer Ron","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-06-14T21:25:58.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the annual grant of restricted stock units (\"RSUs\")  made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest one year from the grant date, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":87658,"source":{"system":"sec-edgar","filing":"0001628280-24-028343","document":"wk-form4_1718400349.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454001/000162828024028343/wk-form4_1718400349.xml","form_type":"4"}},{"id":1478392,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":41602,"kind":"person","name":"Monges Viviane","position":1,"cik":"0001838204","reported_name":"Monges Viviane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-06-14T21:23:18.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the annual grant of restricted stock units (\"RSUs\") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest one year from the grant date, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":108064,"source":{"system":"sec-edgar","filing":"0001628280-24-028339","document":"wk-form4_1718400187.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1771910/000162828024028339/wk-form4_1718400187.xml","form_type":"4"}},{"id":1479434,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":41821,"kind":"person","name":"Hug Peter","position":1,"cik":"0002000702","reported_name":"Hug Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-06-14T17:40:35.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the annual grant of restricted stock units (\"RSUs\") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest one year from the grant date, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":183837,"source":{"system":"sec-edgar","filing":"0001628280-24-028353","document":"wk-form4_1718401227.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000702/000162828024028353/wk-form4_1718401227.xml","form_type":"4"}},{"id":1520547,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2024-05-10T20:01:19.000Z","date":"2024-05-08","kind":"purchase","planned":false,"acquired":true,"shares":8163265,"price":4.812,"value":39281631.18,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On May 8, 2024, certain private investment vehicles managed by Redmile Group, LLC (\"Redmile\"), including RedCo II Master Fund, L.P. (\"RedCo II\" and collectively with the other private investment vehicles managed by Redmile, the \"Redmile Clients\"), acquired, in an underwritten public offering, pre-funded warrants (the \"Pre-Funded Warrants\") to purchase Common Shares of the Issuer (the \"Pre-Funded Warrant Shares\") at a purchase price per Pre-Funded Warrant equal to $4.812."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price of the Pre-Funded Warrants is CHF 0.08 per Pre-Funded Warrant Share. Based on the May 8, 2024 exchange rate of $1.1013 USD to CHF 1.00, the exercise price of the Pre-Funded Warrants in US Dollars as of May 8, 2024 is approximately $0.088."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrants are exercisable by the holder at any time after their original issuance until the tenth anniversary of their original issuance, subject to a 9.99% beneficial ownership blocker. At any time during the last 90 days of the term of the Pre-Funded Warrants, the holder thereof may exchange a Pre Funded Warrant with the Issuer for a new Pre Funded Warrant to purchase the number of Pre-Funded Warrant Shares then remaining under such Pre-Funded Warrant, with a subsequent ten-year exercise period."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported herein are directly owned by the Redmile Clients, including RedCo II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The reported securities may be deemed beneficially owned by Redmile as investment manager of the Redmile Clients and by Jeremy Green as the managing principal of Redmile. Each of Redmile and Mr. Green (collectively with RedCo II, the \"Reporting Persons\") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":8163265,"derivative":{"exercise_date":"2024-05-08","underlying":"Common Shares","underlying_shares":8163265},"source":{"system":"sec-edgar","filing":"0001104659-24-059881","document":"tm2414067-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465924059881/tm2414067-1_4seq1.xml","form_type":"4"}},{"id":1520546,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2024-05-10T20:01:19.000Z","date":"2024-05-08","kind":"purchase","planned":false,"acquired":true,"shares":6107181,"price":4.812,"value":29387754.972,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On May 8, 2024, certain private investment vehicles managed by Redmile Group, LLC (\"Redmile\"), including RedCo II Master Fund, L.P. (\"RedCo II\" and collectively with the other private investment vehicles managed by Redmile, the \"Redmile Clients\"), acquired, in an underwritten public offering, pre-funded warrants (the \"Pre-Funded Warrants\") to purchase Common Shares of the Issuer (the \"Pre-Funded Warrant Shares\") at a purchase price per Pre-Funded Warrant equal to $4.812."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price of the Pre-Funded Warrants is CHF 0.08 per Pre-Funded Warrant Share. Based on the May 8, 2024 exchange rate of $1.1013 USD to CHF 1.00, the exercise price of the Pre-Funded Warrants in US Dollars as of May 8, 2024 is approximately $0.088."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrants are exercisable by the holder at any time after their original issuance until the tenth anniversary of their original issuance, subject to a 9.99% beneficial ownership blocker. At any time during the last 90 days of the term of the Pre-Funded Warrants, the holder thereof may exchange a Pre Funded Warrant with the Issuer for a new Pre Funded Warrant to purchase the number of Pre-Funded Warrant Shares then remaining under such Pre-Funded Warrant, with a subsequent ten-year exercise period."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are directly owned by RedCo II."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The reported securities may be deemed beneficially owned by Redmile as investment manager of the Redmile Clients and by Jeremy Green as the managing principal of Redmile. Each of Redmile and Mr. Green (collectively with RedCo II, the \"Reporting Persons\") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":6107181,"derivative":{"exercise_date":"2024-05-08","underlying":"Common Shares","underlying_shares":6107181},"source":{"system":"sec-edgar","filing":"0001104659-24-059881","document":"tm2414067-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465924059881/tm2414067-1_4seq1.xml","form_type":"4"}},{"id":1522208,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":32949,"kind":"person","name":"MALLIK AMEET","position":1,"cik":"0001861441","reported_name":"MALLIK AMEET","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2024-05-09T20:06:52.000Z","date":"2024-05-07","kind":"sale","planned":false,"acquired":false,"shares":29731,"price":4.48,"value":133194.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents Common Shares sold by the reporting person to  cover tax withholding obligations in connection with the vesting and settlement of restricted share units."}],"balance_after":1167348,"source":{"system":"sec-edgar","filing":"0001628280-24-022207","document":"wk-form4_1715285190.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861441/000162828024022207/wk-form4_1715285190.xml","form_type":"4"}}],"next_cursor":"2024-05-09T20:06:52.000000Z,1522208"}